This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Miodrag Radulovacki | |
|---|---|
| Name | Miodrag Radulovacki |
| Birth date | 1933 |
| Death date | 2014 |
| Birth place | Kragujevac |
| Nationality | Serbian-American |
| Fields | Neuropharmacology, Sleep medicine, Pharmacology |
| Institutions | University of Illinois Chicago, University of Belgrade, Yale University School of Medicine |
| Alma mater | University of Belgrade |
Miodrag Radulovacki was a Serbian-born neuroscientist and pharmacologist noted for pioneering studies on the neurochemical regulation of sleep and for proposing the adenosinergic/cholinergic hypothesis of sleep regulation. He held appointments at the University of Illinois Chicago and maintained collaborations with researchers at institutions such as Yale University School of Medicine and the University of Belgrade. His work influenced fields ranging from neurophysiology to clinical approaches in sleep medicine and respiratory physiology.
Radulovacki was born in Kragujevac and raised in the former Kingdom of Yugoslavia; his early schooling coincided with events involving the Kingdom of Serbia and post‑World War II restructuring under the Socialist Federal Republic of Yugoslavia. He completed medical and doctoral training at the University of Belgrade Faculty of Medicine, where he engaged with faculty who had ties to laboratories in Paris, London, and Moscow. Subsequent postgraduate work included research visits and exchanges with groups at Yale University School of Medicine, University of Chicago, and other North American centers that shaped his focus on neurochemistry and sleep physiology.
Radulovacki served on the faculty at the University of Illinois Chicago in departments connected with pharmacology and neuroscience, collaborating with investigators from Yale University School of Medicine, Columbia University, Harvard Medical School, and Johns Hopkins University. He established translational research programs that linked bench science to clinical contexts familiar to centers such as Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital. His laboratory maintained partnerships with European groups at the Karolinska Institutet, University of Oxford, University of Cambridge, and the University of Milan, and with Latin American investigators at the University of Buenos Aires and Universidade de São Paulo.
Radulovacki developed influential hypotheses about cholinergic and adenosinergic interactions in the regulation of rapid eye movement sleep and non‑REM sleep, engaging with literature from researchers at Stanford University, Washington University in St. Louis, University of California, San Diego, and University of Pennsylvania. He conducted seminal experiments using pharmacological agents affecting adenosine receptors, muscarinic receptors, and monoaminergic pathways, informing work by groups at Scripps Research, Max Planck Institute for Brain Research, and Cold Spring Harbor Laboratory. His studies on respiratory control during sleep intersected with clinical research on obstructive sleep apnea and collaborations with teams at University of Pittsburgh Medical Center, University of Toronto, and Imperial College London. Radulovacki’s approach influenced neuropharmacology programs at University of California, Los Angeles, McGill University, University of Sydney, and Katholieke Universiteit Leuven.
Radulovacki authored and coauthored articles in journals such as Nature, Science, The Lancet, Journal of Neuroscience, Sleep, and Proceedings of the National Academy of Sciences. His publications addressed adenosine receptor mechanisms, cholinergic modulation of REM sleep, and pharmacological mitigation of sleep‑disordered breathing, cited by investigators at NIH, European Molecular Biology Laboratory, and Wellcome Trust‑funded projects. He held patents and filed intellectual property related to adenosinergic modulators and therapeutic strategies for sleep disorders, interacting with technology transfer offices at University of Illinois Chicago, Yale University, and commercial partners in the biotechnology sector such as firms based in Boston, San Diego, and London.
During his career Radulovacki received recognition from professional societies including the American Academy of Sleep Medicine, American Physiological Society, American Society for Pharmacology and Experimental Therapeutics, and European counterparts such as the European Sleep Research Society. He was invited to deliver named lectures at institutions like Karolinska Institutet, University College London, ETH Zurich, and Instituto Nacional de Neurología y Neurocirugía. Grants and fellowships supporting his work came from agencies including the National Institutes of Health, National Science Foundation, Wellcome Trust, and national research agencies in Serbia and Yugoslavia.
Radulovacki maintained ties to Serbian scientific communities at the University of Belgrade and mentored trainees who went on to positions at Duke University, University of California, San Francisco, Vanderbilt University, and international centers including Seoul National University and The University of Tokyo. His legacy persists in contemporary research programs at institutions such as Brigham and Women’s Hospital, Baylor College of Medicine, and the Salk Institute for Biological Studies, and in clinical practice guidelines informed by work from American Thoracic Society and European Respiratory Society. He is remembered by colleagues from academic societies including Society for Neuroscience, International Association for the Study of Sleep, and American College of Chest Physicians.
Category:Serbian scientists Category:Neuroscientists Category:Pharmacologists